DOCSLIB.ORG

Tonsillopharyngitis - Acute (1 of 10)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tonsillopharyngitis - Acute (1 of 10) Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula • Asymmetry & forward displacement of the soft palate Signs of Upper Airway Obstruction • Stridor • Air hunger • Respiratory distress • Toxic appearance • Cyanosis Management of Complications • All abscesses should be drained • Tonsillectomy if patient has a history of recurrent tonsillitis • Acute tonsillectomy without prior incision 3 EVALUATION FOR GABHS INFECTION • Identify & treat GABHS infection as soon as possible after diagnosis to decrease risk of complications like acute rheumatic fever (ARF), glomerulonephritis, pediatric autoimmune neuropsychiatric disorders associated w/ streptococcal infection (PANDAS) syndrome, & decrease period of contagiousness • GABHS is the most common bacterial pathogen of ATP & warrants antibiotic treatment • GABHS infection should be suspected on clinical & epidemiological grounds & supported by laboratory tests • Viral pathogens are more frequent than bacteria, accounting for about 70-90% of cases in children, & almost 100% in children <3 years of age Signs & Symptoms Suggestive of GABHS Infection • Sore throat/tonsillar swelling/exudates • Swollen anterior cervical nodes • Fever >38ºC (low-grade fever <38ºC in children <3 years old) • Lack of cough, conjunctivitis, rhinorrhea,MIMS hoarseness • Symptoms in a patient aged 5-15 years Signs & Symptoms Suggestive of a Viral Etiology • Rhinorrhea • Cough • Hoarseness • Conjunctivitis • Diarrhea • Oropharyngeal ulceration • Muscle &© joint pain B270 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (3 of 10) 4 DIAGNOSIS • Tests not needed for patients whose features do not suggest GABHS infection • For patients 3-15 years of age, perform diagnostic tests when GABHS cannot be excluded Rapid Antigen Detection Test (RADT) • Advantage of speed (within minutes versus 48 hours for culture) & specifi city (≥95%) for GABHS • Children w/ throat pain w/ ≥2 of the following are recommended to undergo RADT: - Absence of cough TONSILLOPHARYNGITIS - Presence of tonsillar exudates/swelling - History of fever - Age >15 years - Positive for swelling & tenderness of the anterior cervical lymph nodes • Confi rmation w/ culture is not necessary after a negative RADT result roat Swab Culture • Highly sensitive (90-95% sensitivity) but not done routinely because of delay in results (18-24 hours) - Recommended for those w/ history of contact w/ symptomatic persons w/ GABHS pharyngitis, recurrent GABHS infection & symptomatic patients at high risk for rheumatic fever • roat swabs from both tonsils & posterior pharyngeal wall • Optimal time for collection is at onset of symptoms & before antibiotics are started Centor Criteria • Used to assess the susceptibility of patients to GABHS infection based on the patient’s age & symptoms - Results may assist in the decision to start antibiotic treatment • Uses a points system utilizing the following signs/symptoms: - Fever (>38oC) (1) - Absence of cough (1) - Tender anterior cervical node (1) - Tonsillar exudate/swelling (1) - Age 3-14 years (1) - Age 15-44 years (0) - Age >44 years (-1) • Modifi ed total risk based on total ATP score: Total score Risk of GABHS ≥4 51-53% 3 28-35% 2 11-17% 1 5-10% ≤0 1-2.5% FeverPAIN Score • May be used to assess the need to start antibiotic treatment as well as the severity of throat pain • High results may indicate streptococcal infection; results should be correlated w/ Centor criteria score 5 RESPONSE TO THERAPY • Clinical response is usually evident withinMIMS 24-48 hours • Persistence beyond 48 hours may indicate alternative causes or development of suppurative complications which warrants reassessment A SUPPORTIVE MANAGEMENT General Measures • Adequate fl uid intake • Warm saline gargle (¼ teaspoon of salt per 8 oz glass of water) • Elimination of close contact w/ family members or visitors if patient has been confi rmed to have GABHS • Remain at© home until 24 hours of antibiotic therapy has been received Alternative erapy • ere are not enough studies to support use of acupunture & herbal treatments for tonsillopharyngitis Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B271 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (4 of 10) B PHARMACOLOGICAL THERAPY - NON-GABHS INFECTION Symptomatic Treatment • Symptomatic treatment is important in the management of children w/ sore throat Simple Analgesics/Antipyretics • Paracetamol is the drug of choice for analgesia in sore throat • Aspirin is not recommended due to the risk of Reye’s syndrome Nonsteroidal Anti-infl ammatory Drugs (NSAIDs) TONSILLOPHARYNGITIS • Ibuprofen is a safe & eff ective alternative for analgesia & antipyrexia • Diclofenac may also be used for against pain caused by ATP • As NSAIDs are associated w/ signifi cant risk of GI bleeding, their routine use is not recommended roat Lozenges/Gargle/Spray • May be helpful especially in those w/ signifi cant throat pain or discomfort C PHARMACOLOGICAL THERAPY - GABHS INFECTION Symptomatic Treatment • Important in the management of children w/ sore throat • Same as for non-GABHS infection Antimicrobial erapy • Treatment started only for documented GABHS infection • Due to practical constraints, antibiotics may be started empirically if: - GABHS is clinically suspected - Patient is toxic-looking - Follow-up is not possible • Empiric treatment of GABHS is discouraged due to poor diagnostic accuracy even w/ elaborate clinical scoring systems • A RADT or throat swab should be taken before starting empiric antibiotics • If antibiotics are started empirically, & culture results are negative, the antibiotic should be discontinued • Appropriate antibiotics prevent ARF, prevent suppurative complications, decrease infectivity & shorten clinical course Penicillin • Drug of choice • Proven effi cacy, narrow spectrum, safety & low cost • Full 10-day course of treatment for oral medications • IM penicillin may be advisable if poor compliance is a concern Amoxicillin • Better tolerated than Penicillin • 2nd line to Penicillin in pediatric patients due to taste preference Macrolides • Eg Azithromycin, Clarithromycin, Erythromycin, Roxithromycin • May be used for patients w/ Penicillin allergy • Local resistance patterns vary geographically & should be included in the consideration for an alternative antibiotic in Penicillin-allergic patients MIMS • Azithromycin or Cephalexin may be used for Erythromycin-intolerant patients Cephalosporins • Eg Cefaclor, Cefadroxil, Cefdinir, Cefi xime, Cefpodoxime, Cephalexin • Alternative to Amoxicillin for the eradication of streptococcal infection especially in recurrent cases • Studies show that a 5-day treatment w/ a cephalosporin is superior to a 10-day course w/ Penicillin Clindamycin • May be used for those who are both Penicillin-allergic & Erythromycin-intolerant • Reported resistance of GABHS isolates to Clindamycin are generally low & thus may still be considered a reasonable© alternative to macrolides & Penicillin Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B272 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (5 of 10) D SURGERY Treatment Goal • For recurrent tonsillopharyngitis, surgery aims for reduction in occurrence of sore throat & improved general health w/ tonsillectomy Indications for Tonsillectomy Recurrent Tonsillitis • Sore throat due to infl ammation of tonsils TONSILLOPHARYNGITIS • ≥7 episodes of tonsillitis over a 12-month period or ≥5 episodes/year in the past 2 years or ≥3 episodes/year in the past 3 years w/ documentation for each episode of sore throat & ≥1 of the following: - Temperature >38.3°C (101°F) - Cervical adenopathy - Tonsillar exudate - Positive test for GABHS infection • Symptoms interfere w/ patient’s normal daily function Peritonsillar Abscess or Quinsy • All abscesses should be drained • Tonsillectomy if without response to appropriate antibiotics &/or incision & drainage Contraindications to
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Commission Decision of 8 February 2010 Concerning The
    L 36/36 EN Official Journal of the European Union 9.2.2010 COMMISSION DECISION of 8 February 2010 concerning the non-inclusion of certain substances in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (notified under document C(2010) 751) (Text with EEA relevance) (2010/72/EU) THE EUROPEAN COMMISSION, concerned should therefore not be included in Annex I, IA or IB to Directive 98/8/EC. Having regard to the Treaty on the Functioning of the European Union, (6) In the interest of legal certainty, biocidal products Having regard to Directive 98/8/EC of the European Parliament containing active substances for the product-types and of the Council of 16 February 1998 concerning the placing indicated in the Annex to this Decision should no of biocidal products on the market ( 1), and in particular the longer be placed on the market, with effect from a second subparagraph of Article 16(2) thereof, specific date. Whereas: (7) The measures provided for in this Decision are in accordance with the opinion of the Standing (1) Commission Regulation (EC) No 1451/2007 of Committee on Biocidal Products, 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive HAS ADOPTED THIS DECISION: 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the Article 1 market ( 2) establishes a list of active substances to be assessed, with a view to their possible inclusion in The substances indicated in the Annex to this Decision shall not Annex I, IA or IB to Directive 98/8/EC.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • 1 Brief Report: the Virucidal Efficacy of Oral Rinse Components Against SARS-Cov-2 in Vitro Evelina Statkute1†, Anzelika Rubin
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro Evelina Statkute1†, Anzelika Rubina1†, Valerie B O’Donnell1, David W. Thomas2† Richard J. Stanton1† 1Systems Immunity University Research Institute, Division of Infection & Immunity, School of Medicine, Heath Park, Cardiff, CF14 4XN 2Advanced Therapies Group, School of Dentistry, Cardiff University, Heath Park, Cardiff CF14 4XY, UK †These authors contributed equally * Correspondence: [email protected], [email protected] Running title: Virucidal Activity of Mouthwashes Keywords: SARS-CoV2, mouthwash, lipid, envelope Disclosure: Venture Life Group plc provided information on mouthwash formulations employed in the study, but had no role in funding, planning, execution, analysis or writing of this study. A separate study funded to Cardiff University by Venture Life Group is assessing in vivo efficacy of CPC in patients with COVID19. The investigators declare no direct conflicts exist. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.13.381079; this version posted November 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.
    [Show full text]
  • Report Name:Ukraine's Mrls for Veterinary Drugs
    Voluntary Report – Voluntary - Public Distribution Date: November 05,2020 Report Number: UP2020-0051 Report Name: Ukraine's MRLs for Veterinary Drugs Country: Ukraine Post: Kyiv Report Category: FAIRS Subject Report Prepared By: Oleksandr Tarassevych Approved By: Robin Gray Report Highlights: Ukraine adopted several maximum residue levels (MRLs) for veterinary drugs, coccidiostats and histomonostats in food products of animal origin. Ukraine also adopted a list of drugs residues that are not allowed in food products. THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT POLICY The Office of Agricultural Affairs of USDA/Foreign Agricultural Service in Kyiv, Ukraine prepared this report for U.S. exporters of domestic food and agricultural products. While every possible care was taken in the preparation of this report, information provided may not be completely accurate either because policies have changed since the time this report was written, or because clear and consistent information about these policies was not available. It is highly recommended U.S. exporters verify the full set of import requirements with their foreign customers, who are normally best equipped to research such matters with local authorities, before any goods are shipped. This FAIRS Subject Report accompanies other reports on Maximum, Residue Limits established by Ukraine in 2020. Related reports could be found under the following links: 1.) Ukraine's MRLs for Microbiological Contaminants_Kyiv_Ukraine_04-27-2020 2.) Ukraine's MRLs for Certain Contaminants_Kyiv_Ukraine_03-06-2020 Food Products of animal origin and/or ingredients of animal origin are not permitted in the Ukrainian market if they contain certain veterinary drugs residues in excess of the maximum residue levels established in Tables 1 and 2.
    [Show full text]
  • Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr
    _ US005120325A Ulllted States Patent [19] [11] Patent Number: 5,120,325 Dow, Jr. [45] Date of Patent: Jun. 9, 1992 [54] COLOR-MATCHED STERILE ADHESIVE 4,561,435 12/1985 McKnight et al. ............... .. 604/304 BANDAGES CONTAINING MELANINLIKE 4,699,792 10/1987 Nick et a1. 1 . .. 604/307 PIGMENT COMPOSITION 4.710,191 12/1987 Kwiatek et a1. 604/304 4,728,323 3/1988 Matson .............. .. ‘604/304 [75] Inventor: James E. Dow, Jr., Hackensack, NJ. 4,745,916 5/1988 Seber ..... .. 128/155 , 4,895,727 l/l990 Allen 424/642 [731 Asslgnw Fleshtones Products (30-11119, 4,990,144 2/1991 Blott .................................. .. 604/304 Hackensack, NJ. Primary Examiner-David Isabella 1211 Appl- N04 713,827 Assistant Examiner—Dinh X. Nguyen [22] Filed: Jam 12, 1991 Attorney, Agent, or Firm-Carl W1 Battle [51] 11.1.0.5 ..................... .. A61F 13/00; A61F 13/02 [57] ABSTRACT [52] U.S. Cl. .................................. .. 604/304; 604/307; A sterile bandage suitable for external application to a 602/41; 602/42; 602/58 wound or injury of the human skin comprising a back [58] Field of Search .............. .. 604/304, 307; 128/156; ing layer, a non-toxic pigmented composition coated 424/447, 448 onto or embedded into the top side of said backing [56] References Cited layer, wherein said pigmented composition comprises one or more pigments having a melanin likeness in ap U.S. PATENT DOCUMENTS pearance so as to substantially match the appearance of said human skin. 3,987,202 10/1976 Okun ................................... .. 424/70 4,161,176 7/1979 Harris, U et a1.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Quantitative Assessment of Antimicrobial Activity of PLGA Films Loaded with 4-Hexylresorcinol
    Journal of Functional Biomaterials Article Quantitative Assessment of Antimicrobial Activity of PLGA Films Loaded with 4-Hexylresorcinol Michael Kemme * and Regina Heinzel-Wieland Department of Chemical Engineering and Biotechnology, Hochschule Darmstadt, University of Applied Sciences, Stephanstrasse 7, 64295 Darmstadt, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-6151-1638631 Received: 18 December 2017; Accepted: 9 January 2018; Published: 11 January 2018 Abstract: Profound screening and evaluation methods for biocide-releasing polymer films are crucial for predicting applicability and therapeutic outcome of these drug delivery systems. For this purpose, we developed an agar overlay assay embedding biopolymer composite films in a seeded microbial lawn. By combining this approach with model-dependent analysis for agar diffusion, antimicrobial potency of the entrapped drug can be calculated in terms of minimum inhibitory concentrations (MICs). Thus, the topical antiseptic 4-hexylresorcinol (4-HR) was incorporated into poly(lactic-co-glycolic acid) (PLGA) films at different loadings up to 3.7 mg/cm2 surface area through a solvent casting technique. The antimicrobial activity of 4-HR released from these composite films was assessed against a panel of Gram-negative and Gram–positive bacteria, yeasts and filamentous fungi by the proposed assay. All the microbial strains tested were susceptible to PLGA-4-HR films with MIC values down to 0.4% (w/w). The presented approach serves as a reliable method in screening and quantifying the antimicrobial activity of polymer composite films. Moreover, 4-HR-loaded PLGA films are a promising biomaterial that may find future application in the biomedical and packaging sector.
    [Show full text]
  • Chewable Lozenge Formulation
    Umashankar M S et al. Int. Res. J. Pharm. 2016, 7 (4) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Review Article CHEWABLE LOZENGE FORMULATION- A REVIEW Umashankar M S *, Dinesh S R, Rini R, Lakshmi K S, Damodharan N SRM College of Pharmacy, SRM University, Kattankulathur, India *Corresponding Author Email: [email protected] Article Received on: 11/02/16 Revised on: 13/03/16 Approved for publication: 28/03/16 DOI: 10.7897/2230-8407.07432 ABSTRACT Development of lozenges dated back to 20thcentury and is still remain popular among the consumer and hence it has continued commercial production. Lozenges are palatable solid unit dosage form administrated in the oral cavity. They meant to be dissolved in mouth or pharynx for its local or systemic effect. Lozenge tablets provide several advantages as pharmaceutical formulations however with some disadvantages. Lozenge as a dosage form can be adopted for drug delivery across buccal route, labial route, gingival route and sublingual route. Multiple drugs can also be incorporated in them for chronic illness treatments. Lozenge enables loading of wide range of active ingredients for oral systemic delivery of drugs. Lozenges are available as over the counter medications in the form of caramel based soft lozenges, hard candy lozenges and compressed tablet lozenges containing drugs for sore throat, mouth infection and as mouth fresheners. The rationale behind the use of medicated lozenges as one of the most favored dosage form for the delivery of antitussive drugs. This review focuses various aspects of lozenge formulation providing an insight to the formulation scientist on novel application of lozenge drug delivery system.
    [Show full text]
  • Substantial Equivalence Determination Decision Summary Assay Only Template
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k091024 B. Purpose for Submission: Premarket notification C. Measurand: Methicillin Resistant Staphylococcus aureus (MRSA) D. Type of Test: Detection of MRSA using a selective and differential chromogenic media E. Applicant: bioMérieux, Inc. F. Proprietary and Established Names: chromID™ MRSA Agar G. Regulatory Information: 1. Regulation section: 21 CFR 866.1700 2. Classification: Class II 3. Product code: JSO Culture media, Antimicrobial susceptibility test, excluding Mueller Hinton Agar 1 4. Panel: Microbiology H. Intended Use: 1. Intended use(s): chromID™ MRSA agar is a selective and differential chromogenic medium for the qualitative detection of nasal colonization of methicillin resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test is performed on anterior nares swab specimens from patients and healthcare workers to screen for MRSA colonization. chromID™ MRSA agar is not intended to diagnose MRSA infection nor to guide or monitor treatment of infection. 2. Indication(s) for use: The chromID™ MRSA agar is not intended to diagnose MRSA infection nor to guide or monitor treatment of infection. 3. Special conditions for use statement(s): Prescription use 4. Special instrument requirements: Not applicable I. Device Description: The chromID™ MRSA agar is translucent and a light tan color. After the plates are inoculated and incubated, colonies growing on the plates will have either a green appearance, which indicates a positive MRSA status or a colorless appearance which indicates a negative MRSA status. The green color is more vivid if the colonies are observed through the agar from the bottom of the plate.
    [Show full text]
  • Adverse Effects and Precautions
    1736 Disinfectants and Preservatives i Amylmetacresoi (BAN, riNN) ..................Preparat ons........ Adverse Effects and Precautions ProprietaryPreparations (details are given in Volume B) The alkyl gallates may cause contact sensitivity and skin Aml!metacreso!; A[ililrnetakrezol: Amylrnet.acreso[; Amylrne.­ AM<InM<;· Multi-ingredient Preparations. Singapore: Esemdent. reactions. ta�resolurn; Amylmetakresol: Amyylirnetakresoli; TaKpe30J1. Effects on the blood. Methaemoglobinaemia associated 6-Pentyl-rn,cresol; S;Methyl.-2-pentylpheooi. Alkyl Gallates with the antoxidants (butylated hydroxyanisole, butylated C1 J1,80= 178.3 hydroxytoluene, and propyl gallate) used to preserve the CAS 1300,94-3. .de Gaiatos alquilo; AnKwnrannalJ:>t. oil in a soybean infant feed fom1ula has been reported.1 UN!! -'-· 05W904P57F: Propyl gallate was suspected of being the most likely cause Dodecyl Gallate because its chemical structure is similar to pyrogallol Pharmacopoeias. In Bur. (see p. vii). (p. 1718.2), a methaemoglobinaemia inducer. Ph. Eur. 8: (Amylmetacresol). A clear or almost clear liquid Dodecilo galatas; Dociecyle,. gallate Dodecylgallat; . de; ..•. I. Nitzan M, et al. Infantile methemoglobinemia caused by food additives. or a solid crystalline mass, colourless or slightly yellow Dodecyi-9Jilat; D(0ec%lis (iallas:. Dodekyyligallaattl; E312; Clin Toxicol 1979; 15: 273-80. when freshly prepared; it darkens or discolours to dark m Galata • de dodecflo; Laury! Gailate; Laurylum Gafikw ; yellow, brownish-yellow, or pink on keeping. F.p. about 22 }logel\vfn rarinar. Preparations degrees. Practically insoluble in water; very soluble in Dodecyi 3,4,5-trihyc;lroxybenzoate. ...................... alcohol and in acetone. Store in non�metallic airtight (details are given in Volume B) C;ul;lje0$=338.4 ProprietaryPreparations containers. Protect from light.
    [Show full text]